Jacques Vargaftig is an hematologist-oncologist. He has clinical expertise in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes, particularly therapy-related myeloid neoplasms. During his PhD research work with Cancer Research UK, under the supervision of Dr. Dominique Bonnet, he became familiar with animal models of acute leukemia.
He is involved as an investigator in several clinical trials and is the principal investigator for a phase II trial testing a dual inhibitor of the PI3K/AKT/mTOR pathway in high-risk AML (NCT02438761).
Since January 2017, he has been granted reduced clinical practice hours and received funding from the institute’s medical and scientific program, enabling him to split his time between clinical practice and basic research, under the direction of Dr. Leïla Perié (Curie Research Center, UMR168), as part of a study into the dynamics of post-chemotherapy clonal reconstitution, using a barcode mouse model.